101620-10-4

Basic information

• Product Name: 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine
• Synonyms: 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine
• CAS NO: 101620-10-4
• Molecular Formula: C₂₁H₂₉N₃
• Molecular Weight: 323.47506
• Mol File: 101620-10-4.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine(101620-10-4)
• EPA Substance Registry System: 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine(101620-10-4)

Safety Data

• Hazardous Substances Data: 101620-10-4(Hazardous Substances Data)

Usage

General Description

1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine is a chemical compound that belongs to the class of piperazine derivatives. It has a molecular formula C24H32N4 and a molecular weight of 380.54 g/mol. 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine is used as a pharmaceutical intermediate in the synthesis of various drugs and pharmaceutical compounds. It has been found to possess pharmacological properties, including potential antipsychotic and anticonvulsant activities. Due to its biological activities, 1-(4-Aminobutyl)-4-(diphenylmethyl)piperazine is being researched for its potential therapeutic applications in the treatment of psychiatric and neurological disorders. However, further studies are needed to fully understand its mechanism of action and potential clinical applications.

Upstream product

• 101620-09-1 N-{4-[4-(diphenylmethyl)piperazin-1-yl]butyl}isoindoline-1,3-dione 
• 841-77-0 diphenylmethylpiperazine 
• 628-20-6 4-Chlorobutyronitrile 

Downstream Products

• 107755-78-2 N-[3-(pyridin-3-yl)propionyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine 
• 124502-70-1 Quinoline-3-carboxylic acid [4-(4-benzhydryl-piperazin-1-yl)-butyl]-amide 
• 120301-45-3 N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(4-hydroxyphenyl)acrylamide 
• 120314-10-5 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-furan-2-yl-acrylamide 
• 120301-47-5 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(3-fluoro-phenyl)-acrylamide 
• 120301-42-0 N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(4-fluorophenyl)acrylamide 
• 120301-43-1 (E)-N-[4-(4-Benzhydryl-piperazin-1-yl)-butyl]-3-(4-chloro-phenyl)-acrylamide 
• 741291-96-3 C₁₆H₁₉NO₄ 
• 118078-39-0 N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4,5-dihydroxyquinoline-3-carboxamide 
• 118420-35-2 N-[3-(5-fluoro-pyridin-3-yl)acryloyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine 
• 120301-55-5 (E)-N-<4-(4-diphenylmethyl-1-piperazinyl)butyl>-3-(3-pyridyl)acrylamide 
• 118420-47-6 N-[3-(6-methyl-pyridin-3-yl)acryloyl]-4-(4-diphenylmethyl-1-piperazinyl)butylamine 
• 1239953-67-3 N-(4-(4-benzhydrylpiperazin-1-yl)butyl)-7-chloroquinolin-4-amine 

Relevant articles and documents

Synthesis and histamine H1-receptor antagonist activity of 4-(diphenylmethyl)-1-piperazine derivatives with a terminal heteroaryl or cycloalkyl amide fragment

New 4-(diphenylmethyl)-1-piperazine derivatives with a terminal heteroaryl or cycloalkyl amide fragment were synthesized and evaluated for their antihistaminic anticholinergic and antiallergic activities. Tested compounds were found to be moderate to potent in vitro (guinea-pig ileum) histamine H1-receptor antagonists. Derivatives with a four methylene chain (1e-1h) were as potent in vivo (capillary permeability in rats) as cetirizine; the heteroaryl derivatives 1e and 1h were found to be the most active agents. These compounds displayed only weak in vitro (guinea-pig ileum) muscarinic M3-receptor antagonist activity. Compounds 1e and 1g were about 100 times more potent than ketotifen in preventing the compound 48/80-induced histamine release from rat peritoneal mast cells. Derivatives 1e, 1f and 1h did not modify the spontaneous motor activity in rats at 100 mg/kg po. Compound 1e has been selected for further studies.

Synthesis, Structure-activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds

We have previously shown that a "reversed chloroquine (RCQ)" molecule, composed of a chloroquine-like moiety and a resistance reversal-like moiety, can overcome chloroquine resistance in P. falciparum (Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. J. Med. Chem. 2006, 49, 5623. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. J. Med. Chem. 2010, 53, 916). Here, we present an investigation into the Structure-activity relationship of the RCQ structures, resulting in an orally active molecule with good in vitro and in vivo antimalarial activity. We also present evidence of the mode of action, indicating that the RCQ molecules inhibit hemozoin formation in the parasite's digestive vacuole in a manner similar to that of chloroquine.

THIAZOLIDINECARBOXYLIC ACID AMIDE DERIVATIVES AND THEIR THERAPEUTIC USES

Thiazolidinecarboxylic acid amides having combined antiallergic and antiasthmatic activities with an antagonist activity against platelet Activating Factor and having the following general formula (I) STR1